Literature DB >> 11677004

The value of muscle exercise in patients with amyotrophic lateral sclerosis.

V E Drory1, E Goltsman, J G Reznik, A Mosek, A D Korczyn.   

Abstract

The role of physical activity for patients with amyotrophic lateral sclerosis (ALS) is controversial. Twenty-five ALS patients were randomized to receive a moderate daily exercise program (n=14) or not to perform any physical activity beyond their usual daily requirements (n=11). At baseline and after 3, 6, 9 and 12 months, patients were assessed by manual muscle strength testing, the Ashworth spasticity scale, ALS functional rating scale (FRS), fatigue severity scale, a visual analogue scale for musculoskeletal pain and the quality-of-life scale (SF-36). At 3 months, patients who performed regular exercise showed less deterioration on FRS and Ashworth scales, but not on other parameters. At 6 months, there was no significant difference between groups, although a trend towards less deterioration in the treated group on most scales was observed. At 9 and 12 months, there were too few patients in each group for statistical evaluation. Our results show that a regular moderate physical exercise program has a short-lived positive effect on disability in ALS patients and should be recommended.

Entities:  

Mesh:

Year:  2001        PMID: 11677004     DOI: 10.1016/s0022-510x(01)00610-4

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  61 in total

Review 1.  Neuroprotection for amyotrophic lateral sclerosis: role of stem cells, growth factors, and gene therapy.

Authors:  Rachna S Pandya; Lilly L J Mao; Edward W Zhou; Robert Bowser; Zhenglun Zhu; Yongjin Zhu; Xin Wang
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2012-03

2.  Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis.

Authors:  Timothy M Miller; Soo H Kim; Koji Yamanaka; Mark Hester; Priya Umapathi; Hannah Arnson; Liza Rizo; Jerry R Mendell; Fred H Gage; Don W Cleveland; Brian K Kaspar
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-12       Impact factor: 11.205

Review 3.  ALS drug development: reflections from the past and a way forward.

Authors:  Swati Aggarwal; Merit Cudkowicz
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

4.  Strengthening the Case for Cluster Set Resistance Training in Aged and Clinical Settings: Emerging Evidence, Proposed Benefits and Suggestions.

Authors:  Christopher Latella; Carolyn Peddle-McIntyre; Lauren Marcotte; James Steele; Kristina Kendall; Ciaran M Fairman
Journal:  Sports Med       Date:  2021-05-13       Impact factor: 11.136

Review 5.  Diagnostic investigation and multidisciplinary management in motor neuron disease.

Authors:  J A Rocha; C Reis; F Simões; J Fonseca; J Mendes Ribeiro
Journal:  J Neurol       Date:  2005-12       Impact factor: 4.849

6.  Recumbent stepping aerobic exercise in amyotrophic lateral sclerosis: a pilot study.

Authors:  Anjali Sivaramakrishnan; Sangeetha Madhavan
Journal:  Neurol Sci       Date:  2019-02-04       Impact factor: 3.307

Review 7.  Effects of exercise on sleep in neurodegenerative disease.

Authors:  Adeel A Memon; Juliana J Coleman; Amy W Amara
Journal:  Neurobiol Dis       Date:  2020-04-01       Impact factor: 5.996

8.  Moderate exercise delays the motor performance decline in a transgenic model of ALS.

Authors:  Isabel Carreras; Sinan Yuruker; Nurgul Aytan; Lokman Hossain; Ji-Kyung Choi; Bruce G Jenkins; Neil W Kowall; Alpaslan Dedeoglu
Journal:  Brain Res       Date:  2009-12-05       Impact factor: 3.252

Review 9.  Physical activity and neuroprotection in amyotrophic lateral sclerosis.

Authors:  Mary E McCrate; Brian K Kaspar
Journal:  Neuromolecular Med       Date:  2008-02-20       Impact factor: 3.843

10.  A conditioning lesion provides selective protection in a rat model of Amyotrophic Lateral Sclerosis.

Authors:  Colin K Franz; Eric T Quach; Christina A Krudy; Thais Federici; Michele A Kliem; Brooke R Snyder; Bethwel Raore; Nicholas M Boulis
Journal:  PLoS One       Date:  2009-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.